phentermine/topiramate (Qnexa, Qsymia)
Jump to navigation
Jump to search
Indications
- weight reduction (Qsymia refused FDA approval Oct 2010; renamed Qsymia & granted FDA approval July 2012)
- BMI >= 30 or >= 27 with comorbid condition (diabetes, hypertension)
Contraindications
* also see phentermine
Adverse effects
- most common
- potential for causing birth defects & heart problems
* also see contraindications
Notes
- average weight reduction of 20 pounds in one year[4]
More general terms
Components
References
- ↑ Physician's First Watch for October 29, 2010 Massachusetts Medical Society FirstWatch@jwatch.org
Pollack A F.D.A. Rejects Qnexa, a Third Weight-Loss Drug NewYork Times, Oct 28. 2010 - ↑ Prescriber's Letter 19(4): 2012 Drugs for Weight Loss Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=280403&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ FDA News Release: July 17, 2012 FDA approves weight-management drug Qsymia http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm312468.htm
- ↑ 4.0 4.1 Prescriber's Letter 19(11): 2012 Drugs for Weight Loss Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=281109&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ 5.0 5.1 Medical Knowledge Self Assessment Program (MKSAP) 17, 19 American College of Physicians, Philadelphia 2015. 2022